|
Abnormal behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, we report for the first time that Jmjd2 class demethylases are critical epigenetic regulators involved in etiopathology of depression and related disorders and activation of these demethylases can be a good strategy in the treatment of MDD and related psychiatric disorders.
|
27711046 |
2017 |
|
Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Non-small-cell lung cancer (NSCLC) patients with adenocarcinoma histology who were homozygous for KDM4A single nucleotide polymorphism (SNP)-A482 (rs586339) were recently shown to have significantly worse overall survival (OS) compared with patients with the wild-type or the heterozygous genotype at this locus (hazard ratio=1.68, P=0.042).
|
28059867 |
2017 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, our results demonstrate that JMJD2A accelerates malignant progression of liver cancer cells in vitro and in vivo.
|
28467776 |
2017 |
|
Advanced breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
|
25193278 |
2014 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.
|
25231870 |
2014 |
|
Agenesis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We now report that JMJD2A could promote breast cancer progression through transcriptional repression of the tumor suppressor aplasia Ras homolog member I (ARHI).
|
24886710 |
2014 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The expression levels of <i>JHDM1A</i>, <i>JHDM2A/2B</i>, and <i>JHDM3A/3B</i> were significantly higher in postmortem brain tissue from patients with AD than from non-demented controls, whereas <i>JHDM1B</i> mRNA levels were downregulated in the brains of patients with AD.
|
31436053 |
2019 |
|
Aortic Valve Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lgr4 activates Jmjd2a/AR signaling pathway to promote interaction AR with PSA promoter, causing reduction of PCa apoptosis and cell cycle arrest.
|
27743893 |
2016 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
They also suggest that KDM4A might serve as a potential target for epigenetic therapy in prevention and treatment of inflammatory diseases such as atherosclerosis.
|
29383092 |
2017 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
They also suggest that KDM4A might serve as a potential target for epigenetic therapy in prevention and treatment of inflammatory diseases such as atherosclerosis.
|
29383092 |
2017 |
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings revealed that JMJD2A may act as an oncogene and participate in bladder cancer progression, which provides a promising therapeutic strategy for patients with bladder cancer.
|
31364745 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Oncogenic features of the JMJD2A histone demethylase in breast cancer.
|
22948256 |
2012 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of Sp1 autoregulation by JMJD2A contributed to Sp1 expression pattern in breast cancer.
|
25193278 |
2014 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
JMJD2A-specific siRNA was chemically synthesised and transfected into human breast cancer cell line MDA-MB-231.
|
21962223 |
2011 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Results from knockdown of JMJD2A, overexpression of JMJD2A, Co-immunoprecipitation (Co-IP) assay, dual luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) elucidated molecular mechanisms of JMJD2A action in breast cancer progression.
|
24886710 |
2014 |
|
Carcinogenesis
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Various human cancers exhibit elevated protein levels of KDM4A-D members, and their depletion impairs tumor formation, suggesting that their enhanced activity promotes carcinogenesis.
|
23589305 |
2013 |
|
Carcinogenesis
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
The histone lysine demethylase KDM4A/JMJD2A has been implicated in prostate carcinogenesis through its role in transcriptional regulation.
|
27626669 |
2016 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Jumonji C domain 2A (JMJD2A), as a histone demethylases, plays a vital role in tumorigenesis and progression.
|
28693517 |
2017 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Jumonji domain-containing protein 2A (JMJD2A) of the JMJD2 family of histone lysine demethylases has been implicated in tumorigenesis.
|
31677131 |
2019 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
The critical role of lysine demethylase 4A (KDM4A), in regulating chromatin structure and consequently in driving cellular proliferation and oncogenesis has been the focus of recent studies.
|
28059867 |
2017 |
|
Carcinogenesis
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
|
26731476 |
2016 |
|
Carcinogenesis
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
JMJD2A is a transcriptional cofactor and enzyme that catalyzes demethylation of histone H3 lysines 9 and 36 and is overexpressed in human tumors, but its role in oncogenesis remains unclear.
|
22134899 |
2012 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Previous studies have shown that the Jumonji domain containing 2A (JMJD2A) was aberrantly expressed in various tumors and involved in the regulation of tumor progression, but the role of JMJD2A on the tumorigenesis in NSCLC and the underlying mechanisms are still unclear.
|
26498874 |
2016 |
|
Carcinogenesis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these results elucidated a novel mechanism - ERG promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1.
|
27109047 |
2016 |